308283-47-8

Usage

Uses

Used in Pharmaceutical Industry:
3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE is used as an intermediate for the preparation of benzamides, which are selective angiotensin II AT2 receptor agonists. These agonists have potential therapeutic applications in treating various conditions, such as hypertension, heart failure, and other cardiovascular diseases, by modulating the activity of the angiotensin II AT2 receptor.
3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE's role as an intermediate in the synthesis of benzamides highlights its importance in the development of novel drugs with specific targeting capabilities. By understanding the compound's properties and potential applications, researchers and pharmaceutical companies can continue to innovate and create new treatments for a wide range of medical conditions.

InChI:InChI=1/C10H14BrNO2S/c1-10(2,3)12-15(13,14)9-6-4-5-8(11)7-9/h4-7,12H,1-3H3

Upstream product

• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 75-64-9 tert-butylamine 

Downstream Products

• 936092-53-4 N-(tert-butyl)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)benzenesulfonamide 
• 936091-14-4 TG101209 
• 936091-56-4 N-tert-butyl-3-[5-methyl-2-(3-morpholin-4-ylmethyl-phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide 
• 1059104-16-3 N-tert-butyl-3-isobutylbenzenesulfonamide 
• 1059104-19-6 3-benzyl-N-tert-butyl-benzenesulfonamide 
• 89599-01-9 3-bromobenzenesulfonamide 
• 936091-26-8 N-tert-butyl-3-{5-methyl-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-benzenesulfonamide 
• 1310496-34-4 3-(4-(3-cyclopropyl-1H-pyrazol-5-ylamino)-5-bromopyrimidin-2-yl)-N-tert-butylbenzenesulfonamide 
• 706820-95-3 N-(tert-butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide 

Relevant academic research and scientific papers

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical composi

PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS

The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.

Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships

In the investigation of the structure-activity relationship of nonpeptide AT2 receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT2 receptor agonist M024 have been synthesised. In a second ser

Acetylenyl-pyrazolo-pyrimidine derivatives

The present invention relates to compounds of formula (I): wherein R1 to R3, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

Heterosubstituted pyridine derivatives as PDE 4 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). The invention also